Highlights Innoviva, Inc.

Equities

INVA

US45781M1018

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
15.26 ^USD	+1.80%		+2.07%	-4.86%

Apr. 24	Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.?s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024	CI
Mar. 04	Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.?s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024	Apr. 24	CI
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.	Feb. 29	CI
Earnings Flash (INVA) INNOVIVA Reports Q4 Revenue $85.8M	Feb. 29	MT
Innoviva, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 29	CI
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.	Nov. 01	CI
Innoviva, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01	CI
Earnings Flash (INVA) INNOVIVA Posts Q3 Revenue $67.3M	Nov. 01	MT
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.	23-08-02	CI
Earnings Flash (INVA) INNOVIVA Reports Q2 Revenue $81M	23-08-02	MT
Innoviva, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-02	CI
Innoviva Unit Says FDA Approves Xacduro for Treatment of Hospital-Acquired, Ventilator-Associated Bacterial Pneumonia	23-05-24	MT
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.	23-05-09	CI
Earnings Flash (INVA) INNOVIVA Posts Q1 Revenue $76.4M	23-05-09	MT
Innoviva, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Innoviva Says US FDA Panel Recommends Approval of Sulbactam-Durlobactam	23-04-17	MT
Innoviva Says FDA's Antimicrobial Drugs Advisory Committee to Convene in April to Review New Drug Application for Sulbactam-Durlobactam	23-03-14	MT
Innoviva, Inc. Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic	23-03-13	CI
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.	23-02-28	CI
Innoviva, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28	CI
Earnings Flash (INVA) INNOVIVA Reports Q4 Revenue $65.8M	23-02-28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Innoviva, Inc.

Equities

INVA

US45781M1018

Highlights

Filters